Syros Pharmaceuticals Inc (NASDAQ:SYRS) shares shot up 16.3% on Tuesday . The stock traded as high as $15.56 and last traded at $13.61, with a volume of 367,076 shares. The stock had previously closed at $11.70.

Several research firms have weighed in on SYRS. Cowen and Company began coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating on the stock. JMP Securities began coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating and a $22.00 price target on the stock. Wedbush began coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating and a $18.00 price target on the stock. Piper Jaffray Cos. began coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “overweight” rating and a $20.00 price target on the stock. Finally, HC Wainwright began coverage on Syros Pharmaceuticals in a research report on Monday, July 18th. They set a “neutral” rating and a $10.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $17.50.

The company has a 50-day moving average of $11.72 and a 200 day moving average of $12.59. The firm’s market capitalization is $316.72 million.

In other Syros Pharmaceuticals news, Director Robert Nelsen bought 400,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 6th. The shares were bought at an average price of $12.50 per share, for a total transaction of $5,000,000.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Redmile Group, Llc bought 432,746 shares of the business’s stock in a transaction that occurred on Wednesday, July 6th. The shares were acquired at an average price of $12.50 per share, for a total transaction of $5,409,325.00. The disclosure for this purchase can be found here.

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.